Autres langues Bolt Biotherapeutics, Inc.

Actions

BOLT

US0977022039

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 09/10/2026			Varia. 5j.	Varia. 1 janv.
4,110 ^USD	+12,60%		+19,13%	-24,84%

11/08	Bolt Biotherapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
12/05	Bolt Biotherapeutics publie ses résultats financiers du premier trimestre 2026	RE

Autres langues

11/08	Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot
11/08	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
11/08	Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
12/05	Bolt Biotherapeutics reports first quarter 2026 financial results
12/05	Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot
12/05	Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
12/05	Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
17/04	Bolt Biotherapeutics : BDC-4182 AACR Poster (BBI-4182-101 TiP AACR 2026 Final)
12/03	Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot
12/03	Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
12/03	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
12/03	Bolt Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt
24/02	Bolt Biotherapeutics to Participate in Upcoming March Conferences
22/01	Alert wrongly tagged to Bolt Biotherapeutics Inc withdrawn
15/01	Bolt appoints Olta Andoni as SVP of legal and people to support platform expansion across checkout, identity, and payments
12/11	Bolt Biotherapeutics Q3 collaboration revenue doubles
12/11	Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot
12/11	Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
12/11	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
02/10/25	Bolt Biotherapeutics, Inc. Announces Reduction of its Current Workforce by Approximately 20 Employees, or Approximately 50% of its Workforce
02/10/25	Bolt Biotherapeutics, Inc. Provides Update on Ongoing Phase 1 Dose Escalation Study of BDC-4182
02/10/25	Washington Shutdown Continues as US Equity Futures Trade Mixed Ahead of Opening Bell
02/10/25	Top Premarket Decliners
01/10/25	Bolt Biotherapeutics to Cut Workforce by 50%; Cancer Drug Trial Data Expected in Q3 of 2026
01/10/25	Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027